CMS Withdraws Skin Substitute Reimbursement Rules, Benefiting BioStem
Event summary
- CMS withdrew all seven Local Coverage Determinations (LCDs) for skin substitute grafts, effective January 1, 2026.
- The LCDs pertained to treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU).
- BioStem Technologies CEO Jason Matuszewski stated the withdrawal won't impact patient access to BioStem’s VENDAJE® and VENDAJE AC® products.
- BioStem intends to continue investing in clinical data to demonstrate the performance of its technology.
The big picture
The CMS’s decision to withdraw these LCDs represents a temporary reprieve for BioStem and other skin substitute manufacturers facing reimbursement pressures. This move suggests a broader reassessment of coverage policies for advanced wound care therapies, potentially reflecting a desire to balance innovation with fiscal responsibility. However, the long-term reimbursement landscape remains uncertain, and BioStem's success hinges on its ability to demonstrate clinical value and navigate evolving regulatory frameworks.
What we're watching
- Reimbursement Risk
- While the current withdrawal is positive, future CMS policy shifts remain a significant risk to BioStem's revenue model, requiring ongoing engagement with policymakers.
- Clinical Validation
- BioStem’s commitment to evidence-based strategy will be critical; the company must consistently generate and publish data demonstrating superior clinical outcomes to justify pricing and maintain market position.
- Competitive Landscape
- The absence of restrictive LCDs may encourage increased competition within the skin substitute market, potentially impacting BioStem’s pricing power and market share.
Related topics